InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
InnoCare Appoints Xin Fu as Chief Financial Officer
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332
Data of InnoCare’s Oncology Pipelines Presented at the 65th Meeting of ASH
InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China